Full List Of Stories
Motif Bio files shelf registration in the US
Clinical-stage biopharmaceutical company Motif Bio announced on Friday that it has filed a ‘universal’ shelf registration statement on Form F-3 with the US Securities and Exchange Commission.
Altus acquisiton of Legend projects moves a step closer
Africa-focussed exploration project generator Altus Strategies announced on Friday that Legend Gold had received the requisite shareholder approval in connection with the proposed plan of arrangement as agreed between Altus and Legend and announced on 21 November last year.
Impax completes acquisition of partner Pax Asset Management
Impax Asset Management Group announced on Friday that, further to its statement on 18 September last year, the acquisition of Pax World Management had completed following the admission to trading on AIM of the 2,665,989 consideration shares on Thursday.
Weatherly posts bumper production at Tschudi
Weatherly International issued its update for the quarter to 31 December on Friday, reporting that Tschudi cathode production improved by 15% quarter-on-quarter to 4,739 tonnes, which was 11. 5% above nameplate over the quarter.
French esports franchise ARES joins Gfinity's Elite Series
Esports entertainment group Gfinity announced on Friday that Paris-based esports franchise ARES has acquired its place on the roster at the Gfinity Elite Series season three, which is due to commence in March.
GoldStone looks into revitalising old Akrokeri mine
GoldStone Resources announced on Friday that, as part of its review of historical data, it has initiated a project to potentially revitalise the old Akrokeri underground mine.
Blancco board positive as it continues hunt for new CEO
Mobile device diagnostics and secure data erasure solutions provider Blancco Technology Group issued a trading update for the six months to 31 December on Friday, in advance of its half yearly results which would be announced on 20 March.
EQTEC makes partial early repayment on secured loan facility
Technology solutions company for waste gasification to energy projects EQTEC announce on Friday that it has made a partial repayment of £378,882 on its secured loan facility, which comprises a five-year term loan of £1m at 15% per annum fixed rate of interest, with Ecofinance GLI.
RM2 urgently seeks cash as bank balance rapidly dwindles
Sustainable pallet developer RM2 International updated the market on its cash position on Friday, having previously provided estimated information on its expected cash resources position over the following eight weeks on 1 December last year.
Character Group confident despite recent headwinds
Branded toys, games and giftware developer The Character Group issued an update on itrs trading on Friday morning, as investors gathered for its annual general meeting.
Sky a standout in the latest Ofcom complaints data
Ofcom published its latest data on the volume of consumer complaints it received against major providers of telecoms and pay-TV services on Friday, revealing a slight uptick in the number of grievances levelled against landline and television providers.
Asia report: Most markets end week on positive note
Most Asian markets finished in the green on Friday, despite whirling concerns of a government shutdown across the Pacific in the United States.
Record upbeat after third quarter performance
Specialist currency manager Record announced on Friday that its assets under management equivalents (AUME) at the end of its third quarter on 31 December totalled $63. 9bn, up from $61. 2bn at the start of the quarter.
Gama Aviation reports strong year amid ongoing legal battles
Business aviation services provider Gama Aviation updated the market on its trading for the full year to 31 December 2017 on Friday, in advance of the publication of its full year results.
AstraZeneca gets approvals for Fasenra and Lynparza in Japan
AstraZeneca announced the approval of two of its drugs in Japan on Friday - Fasenra (benralizumab) as an add-on treatment for bronchial asthma in patients who continue to experience asthma exacerbations despite treatment with high-dose inhaled corticosteroid and other asthma controllers, and Lynparza (olaparib) tablets at 300mg twice daily, for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.